Kathleen CPA - Silverback Therapeutics Chief Officer
| SPRY Stock | 10.87 0.36 3.43% |
Insider
Kathleen CPA is Chief Officer of Silverback Therapeutics
| Address | 11682 El Camino Real, San Diego, CA, United States, 92130 |
| Phone | 858 771 9307 |
| Web | https://ars-pharma.com |
Silverback Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1623) % which means that it has lost $0.1623 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2241) %, meaning that it created substantial loss on money invested by shareholders. Silverback Therapeutics' management efficiency ratios could be used to measure how well Silverback Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.22 in 2025. Return On Capital Employed is likely to rise to -0.32 in 2025. At this time, Silverback Therapeutics' Non Current Assets Total are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 329.5 M in 2025, whereas Total Assets are likely to drop slightly above 136 M in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| Tomasz Kula | Tscan Therapeutics | N/A | |
| AnneMarie LiKwaiCheung | Wave Life Sciences | N/A | |
| John CPA | Windtree Therapeutics | 60 | |
| Ronald Dundore | Windtree Therapeutics | 69 | |
| Stephen Lake | Wave Life Sciences | N/A | |
| Larry Mattheakis | Annexon | 67 | |
| Jonathan Rosin | Wave Life Sciences | N/A | |
| Arnon Rosenthal | Annexon | 68 | |
| Waldemar Priebe | Cns Pharmaceuticals | N/A | |
| Sridhar Vaddeboina | Wave Life Sciences | N/A | |
| Dr III | Cue Biopharma | 49 | |
| Brian JD | Tscan Therapeutics | 55 | |
| Steven Almo | Cue Biopharma | 64 | |
| Steen Knudsen | Allarity Therapeutics | 64 | |
| Ted Yednock | Annexon | 67 | |
| MD FAAAAI | Palisade Bio | N/A | |
| Claus Pedersen | Allarity Therapeutics | 52 | |
| Sharon McBrayer | Palisade Bio | N/A | |
| MD DrSc | Allarity Therapeutics | 81 | |
| Kenneth LaMontagne | In8bio Inc | N/A | |
| Gavin MacBeath | Tscan Therapeutics | 55 | |
Management Performance
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.16 |
Silverback Therapeutics Leadership Team
Elected by the shareholders, the Silverback Therapeutics' board of directors comprises two types of representatives: Silverback Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Silverback. The board's role is to monitor Silverback Therapeutics' management team and ensure that shareholders' interests are well served. Silverback Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Silverback Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, CoFounder Officer | ||
| Kathleen CPA, Chief Officer | ||
| Alexander Esq, Chief Secretary | ||
| Daniel Relovsky, Senior Marketing | ||
| Eric Karas, Chief Officer | ||
| Justin Chakma, Chief Secretary | ||
| Brian MS, SVP Management | ||
| MBA MBA, Ex Strategy | ||
| Robert Bell, CoFounder Officer | ||
| Harris MBA, Executive Strategy | ||
| MBA MS, President, Founder |
Silverback Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Silverback Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.16 | ||||
| Operating Margin | (10.52) % | ||||
| Current Valuation | 784.83 M | ||||
| Shares Outstanding | 97.19 M | ||||
| Shares Owned By Insiders | 23.83 % | ||||
| Shares Owned By Institutions | 75.42 % | ||||
| Number Of Shares Shorted | 16.48 M | ||||
| Price To Book | 4.92 X | ||||
| Price To Sales | 397.75 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Silverback Stock Analysis
When running Silverback Therapeutics' price analysis, check to measure Silverback Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Silverback Therapeutics is operating at the current time. Most of Silverback Therapeutics' value examination focuses on studying past and present price action to predict the probability of Silverback Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Silverback Therapeutics' price. Additionally, you may evaluate how the addition of Silverback Therapeutics to your portfolios can decrease your overall portfolio volatility.